Abstract (EN):
Primacenes, novel ferrocene-primaquine conjugates, were synthesized and screened for their
activity on both the liver-stage and sporogonic development of Plasmodium berghei. Distinct
structural requirements were relevant towards optimal activity against those two different stages of
the malaria parasite’s life-cycle. Primacenes obtained by coupling ferrocenoic acid to 8-amino-6-
methoxyquinoline (MAQ), primaquine (PQ) or PQ derivatives, while significantly active against
Pneumocystis carinii and devoid of cytotoxicity, lacked antimalarial activity in vivo as transmissionblocking
agents [1] and were moderately active in vitro against liver stage parasites. Having
ascribed such loss of anti-Plasmodium activity to the absence of an aliphatic amine group [2-5], we
prepared second-generation primacenes bearing such an aliphatic amine and found them to
display transmission-blocking activity comparable to or even superior than that of PQ [6].
Interestingly, direct attachment of an alkylferrocene to MAQ yielded a primacene (BIC-601) that is
highly active in vitro against liver stage Plasmodia. In vivo liver-stage activity and oral
bioavailability of BIC-601 are now under evaluation.
Language:
English
Type (Professor's evaluation):
Scientific